Approach and progress

Materiality assessment

The assessment identified and assessed the potential environmental, social, employee-related, human rights and combatting corruption topics that could affect the company’s business performance. It was performed considering the reporting requirements of the Swiss Code of Obligations and the reporting standard of the Global Reporting Initiative (GRI).

During 2024, medmix updated the materiality assessment completed during the previous year, adding an additional financial perspective and further risks and opportunities from Enterprise Risk Management (ERM).

The following steps were taken during the assessment process:

The following materiality matrix shows the relevance of the material topics to medmix and to people and the environment:

As a result of the assessment and material topic grouping, medmix identified six material issues, which are aligned with the business strategies, priorities and actions:

While water was not identified as a material topic, information regarding its related measures, activities and performance is included in this report anticipating interest from external parties.

Concepts

This section describes the key medmix regulations, being the concepts and policies, directives and strategies adopted with regards to the five non-financial matters (NFMs) defined in the Swiss Code of Obligations: environment, social, employment, human rights and combatting corruption, and their relationship to the medmix material issues:

Where a document is publicly available, the link is included in the relevant section.

Applying and Reporting medmix’ Sustainability Commitments

To achieve medmix’ stated objectives, both internal and external sustainability commitments have been established. Their aims are reducing environmental impacts; contributing to society; contributing to cost savings through improved efficiency and waste reduction; increasing attractiveness to customers and investors; enhancing reputation and brand value, thereby increasing customer loyalty; driving innovation and competitiveness through the development of new products and processes that are more responsible; and improving employee engagement by aligning with their values and helping attract and retain talent.

This guideline states the timeframe for compliance with the commitments, defining the thresholds of applicability of specific commitments, and providing guidance on any exceptions. It was developed to address the climate change, safety, health & wellbeing and sourcing & circularity material issues.

Code of Business Conduct

medmix is committed to preventing corruption and has a zero-tolerance policy towards corrupt practices.

The purpose of this code is to provide guidance for business behavior in critical areas relating to the business activities of medmix. The code does not cover every situation where compliance or ethical behavior may be required, but rather sets forth clear expectations and a spirit which are fundamental to the way we conduct our business.

We have established a system for monitoring and reporting corruption and for investigating and addressing corruption-related issues.

The medmix Code of Business Conduct was adopted to address the compliance & integrity, human rights and safety, health & wellbeing material issues.

Business Partner Code of Conduct

We have established a Business Partner Code of Conduct outlining our key ethical and compliance values, including integrity, respect for human rights and adherence to applicable laws and regulations. This code sets clear expectations for third parties with whom we conduct business, ensuring alignment with our standards. All business partners are requested to comply with these principles.

The Business Partner Code of Conduct was adopted to address the climate change, compliance & integrity, human rights, safety, health & wellbeing and sourcing & circularity material issues.

Climate Scenario Analysis

Due to the importance of understanding and preparing for climate-related risks, and in line with the Task Force on Climate-related Financial Disclosures (TCFD) recommendations, we analyzed the physical and transitional climate-related risks across multiple future scenarios to enhance the resilience of our strategies and improve information disclosure.

Our climate scenario analysis assessed the potential impacts of these risks on our operations, financial performance and strategic goals, considering their short-term, medium-term and long-term impacts:

Our analysis identified several key climate-related risks:

In addition to these risks, we identified several climate-related opportunities:

• More efficient production processes and transitioning to lower-emission energy sources.
• Participation in carbon markets, developing new products and services through innovation and diversifying business activities.
• Accessing new markets and improving ratings by sustainability and ESG indices, providing significant competitive advantages.

The climate scenario analysis was completed to address the climate change material issue.

Due diligence in relation to child labor and minerals and metals

In line with the requirement of the Swiss Code of Obligations to undertake due diligence into any reasonable suspicion of child labor within medmix and the supply chain, and in relation to the importation and use of conflict minerals and metals, medmix established internal investigative and assessment processes and performed thorough reviews into these topics.

Having completed the required assessments, no suspicious cases of child labor were identified, and medmix does not use any of the listed conflict minerals or metals.

Therefore, medmix is not required to report on due diligence, and any information in this report is being provide anticipating interest from external parties.

The due diligence processes were established to address the compliance & integrity and human rights material issues.

Eco-design Principles

medmix is committed to environmentally sound business practices in our product development. A key component of our strategy is our eco-design approach, enabling the development and launch of sustainable products. The principles are applied consistently across the five business units, and they are the defined reference to create products marketed as eco-designed or sustainable.

These principles are aligned with relevant legislation, ensure greenwashing does not occur and address the climate change and sourcing & circularity material issues.

Information Security

At medmix, data confidentiality, data integrity and system availability are cornerstones of our business. The protection of information and systems is paramount, and therefore we continually monitor adherence to industry standards relating to people, processes, data and technology. Ensuring the security of our customer information is a top priority.

Consistent with industry standards such as the National Institute of Standards and Technology (NIST 2.0) Cybersecurity Framework, the International Organization for Standardization (“ISO/IEC”) 27002 and the Control Objectives for Information and Related Technologies (“COBIT”), medmix Information Security Program leverages administrative, technical and physical safeguards to protect the confidentiality, integrity and availability of information.

Such safeguards are designed to:

• Provide for the security and confidentiality of customer, business proprietary and personal information.
• Protect against anticipated threats to the security or integrity of such information.
• Protect against unauthorized access or use of information that could result in material harm to any party.

medmix Information Security is aligned to the six NIST 2.0 Cybersecurity Framework Functions – Govern, Identify, Protect, Detect, Respond and Recover. When considered together, these functions provide a high-level, strategic view of the lifecycle of medmix’ management of cybersecurity risk.

medmix employs an in-depth defense strategy with a number of technical controls supported by comprehensive processes designed to detect and prevent unauthorized activity, addressing the compliance & integrity material issue.

Personal Data Protection

At medmix, we prioritize the protection of personal data. Our comprehensive data protection framework ensures compliance with global data privacy regulations, including the European Union General Data Protection Regulation (EU GDPR).

Our Data Privacy Management System (DMS) includes an appointed Group Data Protection Officer (GDPO) and a network of local Data Protection Officers and deputies across our global sites. These officers and deputies monitor our data protection practices and the compliance with our internal policies and relevant laws and regulations.

We have implemented effective policies and procedures to safeguard personal data. Our Data Privacy Policy stipulates our principles for processing personal data, ensuring personal data protection globally on the same standards for our employees, customers, suppliers and other data subjects.

Regular training sessions are conducted to educate our employees on data protection best practices and their responsibilities.

We treat personal data equally across all our group companies. To facilitate this, we have established an Intra-Group Data Transfer Agreement (IGDTA). This agreement ensures that personal data is consistently protected and managed according to our standards, regardless of where it is processed within our organization.

Our Personal Data Protection addresses the compliance & integrity material issue.

Procurement Directive

The Procurement Directive describes clear criteria for supplier acceptance: acceptance of our Business Partner Code of Conduct, compliance with the General Data Protection Regulation (GDPR) and with environmental requirements, and no compliance risks (money laundering, bribery and corruption, anti-competitive practices, etc.). After their acceptance, suppliers are included in the Accepted Supplier List and regularly reviewed against these criteria throughout our relationship with them.

Violations of these criteria lead, depending on their severity, to temporary or permanent termination of the relationship with the supplier.

Our Procurement Directive addresses the climate change, compliance & integrity and sourcing & circularity material issues.

Quality Focus

medmix is active in the design, development and manufacturing of sophisticated components and finished products for the Healthcare and Consumer & Industrial segments, mostly within the business-to-business (B2B) framework but also as the legal manufacturer of selected products (applicator systems as medical devices and dispensers as machinery) in selected countries.

For the Healthcare segment, medmix is also active as a service provider of specific services such as the filling of dental material and contract manufacturing of combination products.

Device safety and usability, customer satisfaction, high quality of products and a modern, robust infrastructure supported by a framework of well-understood processes all represent key drivers and objectives for our medmix quality management system.

This focus addresses the product safety material issue.

Sustainability Policy

Sustainability is engrained in our corporate strategy and embedded in daily business – with the necessary management frameworks, systems and processes.

Our policy defines the three-tiered approach of People, Planet and Profit, and outlines our commitment to environmentally and socially responsible practices to reduce environmental impacts, enhance the company’s reputation, ensure regulatory compliance, foster innovation and efficiency, and mitigate risk.

The medmix Sustainability Policy considers the material issues of climate change, human rights, safety, health & wellbeing and sourcing & circularity.

Measures adopted

Aligned with the medmix sustainability strategy, the climate-related transition plan (a summary can be found in the Annex) and the identified material issues, our approach includes the following measures and commitments, demonstrating how we act to achieve the Sustainability Development Goals (SDGs).

The main milestones are being satisfactorily met, and the assessment of effectiveness and performance can be found in the Key activities and Main performance indicators sections of this report.

People

• We perform due diligence throughout medmix and our immediate supply chain to identify any cases of reasonable suspicion of child labor and maintain systems to address the risks of forced labor and modern slavery.
  
  Any case of reasonable suspicion of child labor will be investigated and acted upon.
• The health and safety of our employees is paramount, and so we identify and address the risks that could cause harm. Our site management teams engage with their teams to continually improve the working conditions.
  
  All manufacturing sites are to be ISO 45001-certified by 2025.
  
  Continually improve the employee Lost Time Injury Frequency rate by eliminating hazards and mitigating risks.
• We celebrate our diverse global teams and promote their empowerment and inclusion to take advantage of the range of experiences and spirit that sets our company apart. We are signatories to the United Nations Women’s Empowerment Principles and ensure that all employees are treated fairly, respectfully and equally.
  
  Promote inclusion, with an initial focus on diversity.
  
  Virtual learning and training opportunities will be offered to all employees.
  
  medmix benchmarks to living wages¹ and will ensure any gaps from evolving standards of living are closed by 2030.

1) The wage level necessary to afford a decent standard of living for workers and their families, taking into account country circumstances and calculated for work performed during normal hours (International Labour Organization (ILO) definition).

Planet

• Our science-based approach to net zero is intended to mitigate the emissions from our own operations and the most impactful and actionable sections of our value chain. We consider the various scenarios when determining our impacts, risks and opportunities across the natural environment and the surrounding communities.
  
  30% reduction in medmix-own CO_2e absolute emissions by 2025 compared with 2019.
  
  50% reduction in CO_2e carbon footprint absolute emissions by 2030 compared with 2019.
  
  Net zero CO_2e emissions by 2050.
  
  All sites to use electricity from low-carbon sources by 2025.
  
  Submit medmix’ carbon footprint reduction targets to the Science Based Targets initiative (SBTi) for verification.
• Environmental management systems (EMS) provide a structured framework to manage our environmental responsibilities systematically, ensure compliance with regulations, reduce waste and minimize environmental impacts. Additionally, implementing an EMS leads to cost savings through efficient resource use and waste reduction, while also improving the organization’s reputation and stakeholder trust.
  
  All manufacturing sites are to be ISO 14001-certified by 2025.
  
  Manufacturing sites consuming >10’000 GJ of energy per year, representing more than 80% of the total annual medmix energy consumption, are to be ISO 50001-certified by 2025.
• We respect and follow the hierarchy of waste management, where we first act to prevent waste being created and then look to reduce, reuse and recycle what remains, always seeking to obtain value from what we process.
  
  Zero waste will be sent to landfill by 2025.

Profit

• For transparency and accountability, as well as to identify areas of opportunity for improvement, better manage risks and opportunities, and facilitate alignment with regulations, medmix discloses information publicly to obtain impartial feedback on our performance.
  
  medmix CDP Climate Change “C” rating by 2025.
  
  medmix performance assessed through EcoVadis, with a commitment to continual improvement.
• To increase the sales volumes of sustainable, bio-circular and recycled products, medmix develops innovative solutions for our customers that meet their needs while respecting the environment and people.
  
  Increase sales of sustainable products, making 15 available during 2024.

Key activities

To achieve progress through the established measures, the following key activities were undertaken during 2024, and their effectiveness was determined against the key performance indicators set out in the Main performance indicators section:

Description of risks

At medmix, environmental, social and governance (ESG) risks, including sustainability, are assessed regularly and managed as part of the company’s integrated Enterprise Risk Management (ERM) process. This holistic approach ensures that climate-related and other sustainability risks are integrated into the broader organizational risk framework. The Global Sustainability Lead, who reports to the Chief Human Resources and Sustainability Officer (CHRO), is responsible for managing climate-related and other sustainability risks and opportunities. The Global Sustainability Lead provides regular updates to the CHRO as a member of the Executive Committee and, in collaboration with the Chief Compliance Officer, ensures that sustainability risks are incorporated into the annual ERM review. This governance structure ensures operational oversight and accountability for ESG-related risks and opportunities at medmix. The Executive Committee encourages a strong organizational culture and awareness of risk to ensure that the organization can overcome the factors that inhibit effective risk management.

ESG and sustainability risks have been identified through a structured survey process involving internal and external stakeholders. Based on this, medmix has identified 14 material topics, which address environmental, social, and governance (ESG) risks and opportunities, reinforcing medmix’ commitment to responsible and sustainable business practices. The topics are linked to the ERM risk registry, allowing for seamless integration into the broader risk management framework. Risks are assessed based on their potential financial, reputational and social impact on the company and society, and are duly considered in company financial planning.

The annual ERM process provides a platform for identifying, categorizing and prioritizing climate-related risks and opportunities. While mitigation measures are defined during the annual ERM cycle, medmix’ existing management framework supports proactive risk mitigation and adaptation efforts. Measures include:

• Physical risks: monitoring the potential impacts of extreme weather events on operational facilities and ensuring resilience through business continuity planning.
• Transition risks: evaluating changes in regulatory landscapes and market demands, with a focus on maintaining compliance and adapting product portfolios to emerging sustainability trends.

To track progress, medmix monitors specific sustainability key performance indicators (KPIs) associated with its material topics. Progress against these KPIs is regularly reviewed as part of the ERM process. This ensures that climate-related risks and opportunities remain aligned with the company’s strategic objectives and operational priorities.

In addition to managing risks, medmix actively identifies opportunities linked to its material topics. These include potential advances in sustainable product development, improvements in operational efficiency through energy reduction initiatives and enhancements of supply chain resilience.

The following chart outlines the company’s material issues, along with the significant risks identified through the company’s Enterprise Risk Management process, and key activities to mitigate their impact. The significance and relevance of the risks have been determined based on their potential financial, legal, reputational and social impacts: